according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Enrofloxacin / Diclofenac Liquid Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 06.04.2024 1241632-00020 Date of first issue: 26.01.2017 5.0

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name Enrofloxacin / Diclofenac Liquid Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-: Veterinary product

stance/Mixture

Recommended restrictions

on use

Not applicable

1.3 Details of the supplier of the safety data sheet

MSD Company

Kilsheelan

Clonmel Tipperary, IE

Telephone 353-51-601000

E-mail address of person

responsible for the SDS

EHSDATASTEWARD@msd.com

1.4 Emergency telephone number

+1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

Skin corrosion, Category 1 H314: Causes severe skin burns and eye damage.

Serious eye damage, Category 1 H318: Causes serious eye damage. Reproductive toxicity, Category 2 H361f: Suspected of damaging fertility.

Specific target organ toxicity - repeated H372: Causes damage to organs through pro-

exposure, Category 1 longed or repeated exposure. Short-term (acute) aquatic hazard, Cate-H400: Very toxic to aquatic life.

Long-term (chronic) aquatic hazard, Cat-

egory 1

H410: Very toxic to aquatic life with long lasting

effects.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Enrofloxacin / Diclofenac Liquid Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 5.0
 06.04.2024
 1241632-00020
 Date of first issue: 26.01.2017

Hazard pictograms :







Signal word : Danger

Hazard statements : H314 Causes severe skin burns and eye damage.

H361f Suspected of damaging fertility.

H372 Causes damage to organs through prolonged or re-

peated exposure.

H410 Very toxic to aquatic life with long lasting effects.

Precautionary statements : Prevention:

P201 Obtain special instructions before use.

P273 Avoid release to the environment.

P280 Wear protective gloves/ protective clothing/ eye protec-

tion/ face protection.

Response:

P303 + P361 + P353 + P310 IF ON SKIN (or hair): Take off immediately all contaminated clothing. Rinse skin with water or

shower. Immediately call a POISON CENTER/ doctor.

P305 + P351 + P338 + P310 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Immediately call a

POISON CENTER/ doctor. P391 Collect spillage.

Hazardous components which must be listed on the label:

Enrofloxacin

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

| Chemical name | CAS-No. | Classification | Concentration |
|---------------|---------|----------------|---------------|
|---------------|---------|----------------|---------------|

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Enrofloxacin / Diclofenac Liquid Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 5.0
 06.04.2024
 1241632-00020
 Date of first issue: 26.01.2017

| | EC-No. | | (% w/w) |
|---|---------------------------------------|---|--------------|
| | Index-No. | | (70 11/11) |
| | Registration number | | |
| Enrofloxacin | 93106-60-6 | Acute Tox. 4; H302 Repr. 2; H361f STOT RE 1; H372 (cartilage, Testis) Aquatic Acute 1; H400 Aquatic Chronic 1; H410 | >= 10 - < 20 |
| | | M-Factor (Acute aquatic toxicity): 10 M-Factor (Chronic aquatic toxicity): 10 | |
| Benzyl alcohol | 100-51-6 202-859-9 603-057-00-5 | Acute Tox. 4; H302 Acute Tox. 4; H332 Eye Irrit. 2; H319 Acute toxicity estimate Acute oral toxicity: | >= 1 - < 10 |
| Sodium [2-[(2,6-dichlorophenyl)amino]phenyl]acetate | 15307-79-6 239-346-4 | 1.620 mg/kg Acute Tox. 3; H301 Skin Irrit. 2; H315 Eye Irrit. 2; H319 Repr. 2; H361d STOT RE 1; H372 (Gastrointestinal tract, Blood, lymphatic system, Liver, Prostate) Aquatic Chronic 2; H411 | >= 1 - < 2,5 |

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice : In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

Protection of first-aiders : First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Enrofloxacin / Diclofenac Liquid Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 5.0 06.04.2024 1241632-00020 Date of first issue: 26.01.2017

If inhaled If inhaled, remove to fresh air.

> If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical attention immediately.

In case of skin contact In case of contact, immediately flush skin with plenty of water

for at least 15 minutes while removing contaminated clothing

and shoes.

Get medical attention immediately. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of contact, immediately flush eyes with plenty of water In case of eye contact

for at least 15 minutes.

If easy to do, remove contact lens, if worn.

Get medical attention immediately.

If swallowed If swallowed, DO NOT induce vomiting.

If vomiting occurs have person lean forward.

Call a physician or poison control centre immediately.

Rinse mouth thoroughly with water.

Never give anything by mouth to an unconscious person.

4.2 Most important symptoms and effects, both acute and delayed

Risks Causes serious eye damage.

Suspected of damaging fertility.

Causes damage to organs through prolonged or repeated

exposure.

Causes severe burns.

Causes digestive tract burns.

4.3 Indication of any immediate medical attention and special treatment needed

: Treat symptomatically and supportively. Treatment

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

5.2 Special hazards arising from the substance or mixture

fighting

Specific hazards during fire- : Exposure to combustion products may be a hazard to health.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Enrofloxacin / Diclofenac Liquid Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 5.0 06.04.2024 1241632-00020 Date of first issue: 26.01.2017

Hazardous combustion prod: :

ucts

Carbon oxides
Chlorine compounds
Nitrogen oxides (NOx)
Sodium oxides

5.3 Advice for firefighters

Special protective equipment:

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so.

Prevent spreading over a wide area (e.g. by containment or oil

barriers).

Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Soak up with inert absorbent material.

For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absor-

bent.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Enrofloxacin / Diclofenac Liquid Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 5.0
 06.04.2024
 1241632-00020
 Date of first issue: 26.01.2017

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures : See Engineering measures under EXPOSURE

CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust

ventilation.

Advice on safe handling : Do not get on skin or clothing.

Do not breathe mist or vapours.

Do not swallow. Do not get in eyes.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Keep container tightly closed.

Do not eat, drink or smoke when using this product.

Take care to prevent spills, waste and minimize release to the

environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contami-

nated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers

: Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national

regulations.

Advice on common storage : Do not store with the following product types:

Strong oxidizing agents

Self-reactive substances and mixtures

Organic peroxides

Explosives Gases

7.3 Specific end use(s)

Specific use(s) : No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

| Components CAS-N | o. Value type (Form | Control parameters | Basis |
|------------------|---------------------|--------------------|-------|
|------------------|---------------------|--------------------|-------|

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Enrofloxacin / Diclofenac Liquid Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 5.0
 06.04.2024
 1241632-00020
 Date of first issue: 26.01.2017

| | | of exposure) | | |
|--------------------|---------------------------|--------------|-------------------|------------|
| Propylene glycol | 57-55-6 | TWA | 25 ppm | FOR-2011- |
| | | | 79 mg/m3 | 12-06-1358 |
| Enrofloxacin | 93106-60-6 | TWA | 0.2 mg/m3 (OEB 2) | Internal |
| Sodium [2-[(2,6- | 15307-79-6 | TWA | 100 μg/m3 (OEB 2) | Internal |
| dichloro- | | | | |
| phe- | | | | |
| nyl)amino]phenyl]a | | | | |
| cetate | | | | |
| | Further information: Skin | | | |

Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006:

| Substance name | End Use | Exposure routes | Potential health effects | Value |
|------------------|-----------|-----------------|------------------------------|--------------------|
| Benzyl alcohol | Workers | Inhalation | Long-term systemic effects | 22 mg/m3 |
| | Workers | Inhalation | Acute systemic effects | 110 mg/m3 |
| | Workers | Skin contact | Long-term systemic effects | 8 mg/kg bw/day |
| | Workers | Skin contact | Acute systemic effects | 40 mg/kg bw/day |
| | Consumers | Inhalation | Long-term systemic effects | 5,4 mg/m3 |
| | Consumers | Inhalation | Acute systemic effects | 27 mg/m3 |
| | Consumers | Skin contact | Long-term systemic effects | 4 mg/kg bw/day |
| | Consumers | Skin contact | Acute systemic effects | 20 mg/kg bw/day |
| | Consumers | Ingestion | Long-term systemic effects | 4 mg/kg bw/day |
| | Consumers | Ingestion | Acute systemic effects | 20 mg/kg bw/day |
| Propylene glycol | Workers | Inhalation | Long-term local ef- fects | 10 mg/m3 |
| | Workers | Inhalation | Long-term systemic effects | 168 mg/m3 |
| | Consumers | Inhalation | Long-term local ef- fects | 10 mg/m3 |
| | Consumers | Inhalation | Long-term systemic effects | 50 mg/m3 |

Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006:

| Substance name | Environmental Compartment Value | |
|----------------|---------------------------------|-------------|
| Benzyl alcohol | Fresh water | 1 mg/l |
| | Marine water | 0,1 mg/l |
| | Intermittent use/release | 2,3 mg/l |
| | Sewage treatment plant | 39 mg/l |
| | Fresh water sediment | 5,27 mg/kg |
| | Marine sediment | 0,527 mg/kg |

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Enrofloxacin / Diclofenac Liquid Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 5.0
 06.04.2024
 1241632-00020
 Date of first issue: 26.01.2017

| II | Soil | 0,456 mg/kg |
|------------------|---------------------------|---------------------------------|
| Propylene glycol | Fresh water | 260 mg/l |
| | Freshwater - intermittent | 183 mg/l |
| | Marine water | 26 mg/l |
| | Sewage treatment plant | 20000 mg/l |
| | Fresh water sediment | 572 mg/kg dry weight (d.w.) |
| | Marine sediment | 57,2 mg/kg dry weight (d.w.) |
| | Soil | 50 mg/kg dry weight (d.w.) |

8.2 Exposure controls

Engineering measures

Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less guick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Laboratory operations do not require special containment.

Personal protective equipment

Eye/face protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Hand protection

Material : Chemical-resistant gloves

Skin and body protection : Work uniform or laboratory coat.

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection. Equipment should conform to NS EN 14387

Filter type : Combined particulates and organic vapour type (A-P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Physical state : liquid

Colour : light yellow

Odour : No data available

Odour Threshold : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling :

range

No data available

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Enrofloxacin / Diclofenac Liquid Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 5.0 06.04.2024 1241632-00020 Date of first issue: 26.01.2017

Flammability (solid, gas) : Not applicable

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Flash point : No data available

Auto-ignition temperature : No data available

Decomposition temperature : No data available

pH : 10,5 - 11,5

(as aqueous solution)

Viscosity

Viscosity, kinematic : No data available

Solubility(ies)

Water solubility : soluble

Partition coefficient: n-

octanol/water

Not applicable

Vapour pressure : No data available

Relative density : No data available

Density : 1,07 - 1,08 g/cm³

Relative vapour density : No data available

Particle characteristics

Particle size : Not applicable

9.2 Other information

Explosives : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Evaporation rate : No data available

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Enrofloxacin / Diclofenac Liquid Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 5.0
 06.04.2024
 1241632-00020
 Date of first issue: 26.01.2017

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions : Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid : None known.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

Acids

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of : Inhalation

exposure Skin contact

Ingestion Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 2.000 mg/kg

Method: Calculation method

Acute inhalation toxicity : Acute toxicity estimate: > 5 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist Method: Calculation method

Components:

Enrofloxacin:

Acute oral toxicity : LD50 (Rabbit): 500 - 800 mg/kg

LD50 (Rat): > 5.000 mg/kg

LD50 (Mouse): > 5.000 mg/kg

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Enrofloxacin / Diclofenac Liquid Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 5.0 06.04.2024 1241632-00020 Date of first issue: 26.01.2017

Acute dermal toxicity : LD50 (Rabbit): > 2.000 mg/kg

Benzyl alcohol:

Acute oral toxicity : LD50 (Rat): 1.620 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 4,178 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Method: OECD Test Guideline 403

Sodium [2-[(2,6-dichlorophenyl)amino]phenyl]acetate:

Acute oral toxicity : LD50 (Rat): 55 - 240 mg/kg

LD50 (Mouse): 170 - 389 mg/kg

Acute toxicity (other routes of:

administration)

LD50 (Rat): 97 - 161 mg/kg Application Route: Intravenous

LD50 (Mouse): 92 - 147 mg/kg Application Route: Intravenous

Skin corrosion/irritation

Causes severe burns.

Components:

Enrofloxacin:

Result : No skin irritation

Benzyl alcohol:

Species : Rabbit

Method : OECD Test Guideline 404

Result : No skin irritation

Sodium [2-[(2,6-dichlorophenyl)amino]phenyl]acetate:

Result : irritating

Serious eye damage/eye irritation

Causes serious eye damage.

Components:

Enrofloxacin:

Result : Mild eye irritation

Benzyl alcohol:

Species : Rabbit

Method : OECD Test Guideline 405

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Enrofloxacin / Diclofenac Liquid Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 5.0 06.04.2024 1241632-00020 Date of first issue: 26.01.2017

Result : Irritation to eyes, reversing within 21 days

Sodium [2-[(2,6-dichlorophenyl)amino]phenyl]acetate:

Result : Mild eye irritation

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:

Enrofloxacin:

Test Type : Maximisation Test

Exposure routes : Dermal Species : Guinea pig

Result : Not a skin sensitizer.

Benzyl alcohol:

Test Type : Maximisation Test Exposure routes : Skin contact Species : Guinea pig

Method : OECD Test Guideline 406

Result : negative

Germ cell mutagenicity

Not classified based on available information.

Components:

Enrofloxacin:

Genotoxicity in vitro : Test Type: Chromosomal aberration

Result: positive

Genotoxicity in vivo : Test Type: Micronucleus test

Species: Mouse Result: negative

Test Type: Mammalian bone marrow sister chromatid ex-

change

Species: Hamster Result: negative

Test Type: Chromosomal aberration

Species: Rat Result: negative

Benzyl alcohol:

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Enrofloxacin / Diclofenac Liquid Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 5.0
 06.04.2024
 1241632-00020
 Date of first issue: 26.01.2017

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse

Application Route: Intraperitoneal injection

Result: negative

Sodium [2-[(2,6-dichlorophenyl)amino]phenyl]acetate:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: Mouse Lymphoma

Result: negative

Genotoxicity in vivo : Test Type: Chromosomal aberration

Species: CHO Result: negative

Carcinogenicity

Not classified based on available information.

Components:

Enrofloxacin:

Species : Rat
Application Route : Oral
Exposure time : 2 Years
Result : negative

Species: MouseApplication Route: OralExposure time: 2 YearsResult: negative

Benzyl alcohol:

Species : Mouse
Application Route : Ingestion
Exposure time : 103 weeks

Method : OECD Test Guideline 451

Result : negative

Sodium [2-[(2,6-dichlorophenyl)amino]phenyl]acetate:

Species: RatApplication Route: OralExposure time: 2 YearsResult: negative

Species : Mouse

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Enrofloxacin / Diclofenac Liquid Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 5.0 06.04.2024 1241632-00020 Date of first issue: 26.01.2017

Application Route : Oral
Exposure time : 2 Years
Result : negative

Reproductive toxicity

Suspected of damaging fertility.

Components:

Enrofloxacin:

Effects on fertility : Test Type: Two-generation study

Species: Rat

Application Route: Oral

Fertility: LOAEL: 15 mg/kg body weight

Result: Effects on fertility, alteration in sperm morphology

Effects on foetal develop-

ment

Test Type: Development

Species: Rat

Application Route: Oral

Developmental Toxicity: LOAEL: 210 mg/kg body weight Result: Reduced foetal weight, No teratogenic effects

Remarks: Maternal toxicity observed.

Test Type: Development

Species: Rabbit Application Route: Oral

Developmental Toxicity: NOAEL: 25 mg/kg body weight

Result: No fetotoxicity, No teratogenic effects

Reproductive toxicity - As-

sessment

Some evidence of adverse effects on sexual function and

fertility, based on animal experiments.

Benzyl alcohol:

Effects on fertility : Test Type: Fertility/early embryonic development

Species: Rat

Application Route: Ingestion

Result: negative

Remarks: Based on data from similar materials

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Mouse

Application Route: Ingestion

Result: negative

Sodium [2-[(2,6-dichlorophenyl)amino]phenyl]acetate:

Effects on fertility : Test Type: Fertility

Species: Rat, male and female

Application Route: Oral

Fertility: NOAEL: 4 mg/kg body weight

Result: No effects on fertility

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Enrofloxacin / Diclofenac Liquid Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 5.0 06.04.2024 1241632-00020 Date of first issue: 26.01.2017

Effects on foetal develop-

ment

Test Type: Development

Species: Rat

Application Route: Oral

Developmental Toxicity: LOAEL: 1 mg/kg body weight Result: Embryo-foetal toxicity, No teratogenic effects

Test Type: Development

Species: Rabbit

Application Route: Oral

Developmental Toxicity: LOAEL: 5 mg/kg body weight Result: Embryo-foetal toxicity, No teratogenic effects

Reproductive toxicity - As-

sessment

Suspected of damaging the unborn child.

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

Causes damage to organs through prolonged or repeated exposure.

Components:

Enrofloxacin:

Target Organs : cartilage, Testis

Assessment : Causes damage to organs through prolonged or repeated

exposure.

Sodium [2-[(2,6-dichlorophenyl)amino]phenyl]acetate:

Target Organs : Gastrointestinal tract, Blood, lymphatic system, Liver, Prostate

Assessment : Causes damage to organs through prolonged or repeated

exposure.

Repeated dose toxicity

Components:

Enrofloxacin:

Species : Rat

NOAEL : 36 mg/kg

LOAEL : 150 mg/kg

Application Route : Oral

Exposure time : 13 Weeks

Target Organs : Testis

Species: DogNOAEL: 3 mg/kgLOAEL: 9,6 mg/kgApplication Route: OralExposure time: 13 WeeksTarget Organs: cartilage

Species : Cat

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Enrofloxacin / Diclofenac Liquid Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 5.0 06.04.2024 1241632-00020 Date of first issue: 26.01.2017

NOAEL : 25 mg/kg
Application Route : Oral
Exposure time : 30 Days

Remarks : No significant adverse effects were reported

Benzyl alcohol:

Species : Rat NOAEL : 1,072 mg/l

Application Route : inhalation (dust/mist/fume)

Exposure time : 28 Days

Method : OECD Test Guideline 412

Sodium [2-[(2,6-dichlorophenyl)amino]phenyl]acetate:

Species : Rat

LOAEL : 0,25 mg/kg
Application Route : Oral
Exposure time : 98 w

Target Organs : Gastrointestinal tract, Blood, lymphatic system, Liver, Prostate

Species : Dog
LOAEL : 1 mg/kg
Application Route : Oral
Exposure time : 12 w
Target Organs : Blood

Species : Baboon
NOAEL : 0,5 mg/kg
LOAEL : 5 mg/kg
Application Route : Oral
Exposure time : 52 w

Target Organs : Gastrointestinal tract, Blood Symptoms : constipation, Diarrhoea

Aspiration toxicity

Not classified based on available information.

11.2 Information on other hazards

Endocrine disrupting properties

Product:

Assessment : The substance/mixture does not contain components consid-

ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Enrofloxacin / Diclofenac Liquid Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 5.0 06.04.2024 1241632-00020 Date of first issue: 26.01.2017

Experience with human exposure

Components:

Enrofloxacin:

Ingestion : Symptoms: Gastrointestinal disturbance, central nervous sys-

tem effects, Sensitivity to light

Sodium [2-[(2,6-dichlorophenyl)amino]phenyl]acetate:

Ingestion : Symptoms: Abdominal pain, Diarrhoea, constipation, heart-

burn, Ulceration, Dizziness, Headache, Breathing difficulties,

Rash

SECTION 12: Ecological information

12.1 Toxicity

Components:

Enrofloxacin:

Toxicity to fish : LC50 (Lepomis macrochirus (Bluegill sunfish)): 79,5 mg/l

Exposure time: 96 h

LC50 (Oncorhynchus mykiss (rainbow trout)): > 196 mg/l

Exposure time: 96 h

LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l

Exposure time: 96 h

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Hyalella azteca (Amphipod)): > 206 mg/l

Exposure time: 96 h

EC50 (Daphnia magna (Water flea)): 79,9 mg/l

Exposure time: 48 h

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): 3,1

mg/l

Exposure time: 72 h

EC50 (Microcystis aeruginosa (blue-green algae)): 0,049 mg/l

Exposure time: 5 d

M-Factor (Acute aquatic tox- :

icity)

10

Toxicity to daphnia and other : aquatic invertebrates (Chron-

ic toxicity)

NOEC: 9,8 mg/l Exposure time: 21 d

Species: Daphnia magna (Water flea)

NOEC: 5 mg/l Exposure time: 21 d

Species: Daphnia magna (Water flea)

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Enrofloxacin / Diclofenac Liquid Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 06.04.2024 1241632-00020 Date of first issue: 26.01.2017 5.0

> LOEC: 15 mg/l Exposure time: 21 d

Species: Daphnia magna (Water flea)

M-Factor (Chronic aquatic

toxicity)

: 10

Benzyl alcohol:

LC50 (Pimephales promelas (fathead minnow)): 460 mg/l Toxicity to fish

Exposure time: 96 h

aquatic invertebrates

Toxicity to daphnia and other : EC50 (Daphnia magna (Water flea)): 230 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): 770

mg/l Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 310

ma/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Toxicity to daphnia and other : aquatic invertebrates (Chron-

ic toxicity)

NOEC: 51 mg/l Exposure time: 21 d

Species: Daphnia magna (Water flea) Method: OECD Test Guideline 211

Sodium [2-[(2,6-dichlorophenyl)amino]phenyl]acetate:

Toxicity to fish LC50 (Pimephales promelas (fathead minnow)): 166,6 mg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

Toxicity to daphnia and other:

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 80,1 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): 71,9

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 49,2

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Toxicity to fish (Chronic tox-

icity)

NOEC: 0,32 mg/l

Exposure time: 32 d

Species: Pimephales promelas (fathead minnow)

Method: OECD Test Guideline 210

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Enrofloxacin / Diclofenac Liquid Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 5.0 06.04.2024 1241632-00020 Date of first issue: 26.01.2017

Toxicity to daphnia and other : No aquatic invertebrates (Chron-

aquatic invertebrates (Chronic toxicity) NOEC: 10 mg/l Exposure time: 21 d

Species: Daphnia magna (Water flea) Method: OECD Test Guideline 211

12.2 Persistence and degradability

Components:

Benzyl alcohol:

Biodegradability : Result: Readily biodegradable.

Biodegradation: 92 - 96 % Exposure time: 14 d

12.3 Bioaccumulative potential

Components:

Enrofloxacin:

Partition coefficient: n-

: log Pow: 0,5

octanol/water

Benzyl alcohol:

Partition coefficient: n-

octanol/water

: log Pow: 1,05

Sodium [2-[(2,6-dichlorophenyl)amino]phenyl]acetate:

Partition coefficient: n-

octanol/water

: log Pow: 4,51

12.4 Mobility in soil

Components:

Enrofloxacin:

Distribution among environmental compartments : Koc: 5,55

12.5 Results of PBT and vPvB assessment

Product:

Assessment : This substance/mixture contains no components considered

to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of

0.1% or higher.

12.6 Endocrine disrupting properties

Product:

Assessment : The substance/mixture does not contain components consid-

ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Enrofloxacin / Diclofenac Liquid Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 5.0
 06.04.2024
 1241632-00020
 Date of first issue: 26.01.2017

(EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations.

According to the European Waste Catalogue, Waste Codes

are not product specific, but application specific.

Waste codes should be assigned by the user, preferably in

discussion with the waste disposal authorities.

Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number or ID number

ADN : UN 3082
ADR : UN 3082
RID : UN 3082
IMDG : UN 3082
IATA : UN 3082

14.2 UN proper shipping name

ADN : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

N.O.S.

(Enrofloxacin)

ADR : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

N.O.S.

(Enrofloxacin)

RID : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

N.O.S.

(Enrofloxacin)

IMDG : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

N.O.S.

(Enrofloxacin)

IATA : Environmentally hazardous substance, liquid, n.o.s.

(Enrofloxacin)

14.3 Transport hazard class(es)

Class Subsidiary risks

ADN : 9

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Enrofloxacin / Diclofenac Liquid Formulation

| Version | Revision Date: | SDS Number: | Date of last issue: 30.09.2023 |
|---------|----------------|---------------|---------------------------------|
| 5.0 | 06.04.2024 | 1241632-00020 | Date of first issue: 26.01.2017 |

ADR 9 RID 9 **IMDG** 9 **IATA** 9

14.4 Packing group

ADN

Packing group Ш Classification Code M6 Hazard Identification Number : 90 Labels 9

ADR

Packing group Classification Code M6 Hazard Identification Number : 90 Labels 9 Tunnel restriction code (-)

RID

Packing group Classification Code M6 Hazard Identification Number : 90 Labels

IMDG

Packing group Ш Labels 9

F-A, S-F EmS Code

IATA (Cargo)

Packing instruction (cargo 964

aircraft)

Packing instruction (LQ) Y964 Packing group Ш

Labels Miscellaneous

IATA (Passenger)

Packing instruction (passen-964

ger aircraft)

Packing instruction (LQ) Y964 Packing group Ш

Labels Miscellaneous

14.5 Environmental hazards

ADN

Environmentally hazardous yes

Environmentally hazardous yes

Environmentally hazardous yes

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Enrofloxacin / Diclofenac Liquid Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 5.0 06.04.2024 1241632-00020 Date of first issue: 26.01.2017

IMDG

Marine pollutant : yes

IATA (Passenger)

Environmentally hazardous : yes

IATA (Cargo)

Environmentally hazardous : yes

14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

14.7 Maritime transport in bulk according to IMO instruments

Remarks : Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII) Conditions of restriction for the following entries should be considered: Number on list 75, 3

Substance(s) or mixture(s) are listed here according to their appearance in the regulation, irrespective of their use/purpose or the conditions of the restriction. Please refer to the conditions in corresponding Regulation to determine whether an entry is applicable to the placing on the market or not.

If you intend to use this product as tattoo ink, please contact your vendor.

REACH - Candidate List of Substances of Very High

Concern for Authorisation (Article 59).

REACH - List of substances subject to authorisation

(Annex XIV)

Regulation (EC) No 1005/2009 on substances that de-

plete the ozone layer

Regulation (EU) 2019/1021 on persistent organic pollu-

tants (recast)

Regulation (EU) No 649/2012 of the European Parliament and the Council concerning the export and import

of dangerous chemicals

Not applicable

Not applicable

Not applicable

Not applicable

: Not applicable

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Enrofloxacin / Diclofenac Liquid Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 5.0 06.04.2024 1241632-00020 Date of first issue: 26.01.2017

Quantity 1 Quantity 2
E1 ENVIRONMENTAL 100 t 200 t

HAZARDS

Other regulations:

Note the Working Environment Act § 4-1 and § 4-2 on requirements for the employer to protect pregnant employees against discomfort and injury as a result of the work situation and the working environment.

Note the regulation on organization, leadership and participation, chapter 12 on the work of children and young people.

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information : Items where changes have been made to the previous version

are highlighted in the body of this document by two vertical

lines.

Full text of H-Statements

H301 : Toxic if swallowed. H302 : Harmful if swallowed. H315 : Causes skin irritation.

H319 : Causes serious eye irritation.

H332 : Harmful if inhaled.

H361d : Suspected of damaging the unborn child.

H361f : Suspected of damaging fertility.

H372 : Causes damage to organs through prolonged or repeated

exposure.

H400 : Very toxic to aquatic life.

H410 : Very toxic to aquatic life with long lasting effects.H411 : Toxic to aquatic life with long lasting effects.

Full text of other abbreviations

Acute Tox. : Acute toxicity

Aquatic Acute : Short-term (acute) aquatic hazard
Aquatic Chronic : Long-term (chronic) aquatic hazard

Eye Irrit. : Eye irritation
Repr. : Reproductive toxicity
Skin Irrit. : Skin irritation

STOT RE : Specific target organ toxicity - repeated exposure

FOR-2011-12-06-1358 : Norway. Occupational Exposure limits

FOR-2011-12-06-1358 / : Long term exposure limit

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Enrofloxacin / Diclofenac Liquid Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 5.0
 06.04.2024
 1241632-00020
 Date of first issue: 26.01.2017

TWA

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA -European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI -Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to compile the Safety Data Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, http://echa.europa.eu/

Classification of the mixture:

Classification procedure:

| H314 | Based on product data or assessment |
|-------|-------------------------------------|
| H318 | Based on product data or assessment |
| H361f | Calculation method |
| H372 | Calculation method |
| H400 | Calculation method |
| H410 | Calculation method |
| | H318 H361f H372 H400 |

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Enrofloxacin / Diclofenac Liquid Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 5.0 06.04.2024 1241632-00020 Date of first issue: 26.01.2017

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NO / EN